Patent Claims

1. Compounds selected from the group

No.	Name and/or structure
"A3"	2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A5"	2-[4-(3-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A6"	2-[4-(4-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A7"	2-[4-(3-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A8"	2-[4-(4-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A9"	2-[4-(2-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A10"	2-(4-trifluoromethylpiperidin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A11"	2-[4-(3-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A12"	2-[4-(2-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A13"	2-(4-tert-butylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A14"	2-[4-(4-methoxyphenyl)-3-oxopiperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A15"	2-[4-(piperidine-1-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A16"	2-[4-(6-hydroxypyridin-2-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A17"	2-(4-benzoylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A18"	N-pyridin-2-yl-2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]acetamide
"A19"	2-(4-acetylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A20"	2-[4-(morpholine-4-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A21"	2-[4-(3-aminopropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A22"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]pyridine-3-carboxamide
"A23"	2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]-N-pyridin-3-ylacetamide
"A24"	2-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A25"	2-[4-(2-hydroxyethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A26"	2-[4-[2-(2-pyridyl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A27"	2-[4-(piperidine-2-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A28"	4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide
"A29"	2-[3-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A30"	(2R)-1-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide

"A31"	2-[(2R)-2-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A32"	2-[4-(3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A33"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile
"A34"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzamide
"A35"	2-(4-hydroxy-4-phenyl-1-piperidyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A36"	2-[4-(4-fluoro-2-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A37"	2-[4-(2,4-dimethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A38"	2-[4-(2-chloro-4-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A39"	2-[4-(2-chloro-4-fluoro-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A40"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]acetamide
"A41"	2-(3-phenylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A42"	2-[4-(2-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A43"	2-[4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A44"	2-[4-(6-methoxypyridazin-3-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A45"	4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile

"A46"	2-[4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]phenyl]acetonitrile
"A47"	2-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A48"	2-[4-(4-ethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A49"	2-[4-(4-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A50"	2-[4-(4-trifluoromethylphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A51"	2-[4-(6-methoxy-3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A52"	2-[4-(5-methoxy-2-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A53"	2-[4-hydroxy-4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A54"	2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A55"	2-[4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A56"	2-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A57"	2-[4-[2-(1-hydroxy-1-methyl-ethyl)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and

optionally an pharmaceutically acceptable carrier, excipient or vehicle.

3. Compounds according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

4. Compounds according to claim 3 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.

5. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

6. Set (kit) consisting of separate packs of
(a) an effective amount of a compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient.

7. The compound

2-(4-tert-butyl-piperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one ("B1"),
and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

Patent Claims

1. Compounds selected from the group

No.	Name and/or structure
"A5"	2-[4-(3-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A6"	2-[4-(4-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A8"	2-[4-(4-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A9"	2-[4-(2-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A10"	2-(4-trifluoromethylpiperidin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A11"	2-[4-(3-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A13"	2-(4-tert-butylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A14"	2-[4-(4-methoxyphenyl)-3-oxopiperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A15"	2-[4-(piperidine-1-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A16"	2-[4-(6-hydroxypyridin-2-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A18"	N-pyridin-2-yl-2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]acetamide
"A19"	2-(4-acetylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A20"	2-[4-(morpholine-4-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A21"	2-[4-(3-aminopropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A22"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]pyridine-3-carboxamide
"A23"	2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]-N-pyridin-3-ylacetamide
"A24"	2-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A25"	2-[4-(2-hydroxyethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A26"	2-[4-[2-(2-pyridyl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A27"	2-[4-(piperidine-2-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A28"	4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide
"A29"	2-[3-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A30"	(2R)-1-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide

"A31"	2-[(2R)-2-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A32"	2-[4-(3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A33"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile
"A34"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzamide
"A35"	2-(4-hydroxy-4-phenyl-1-piperidyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A36"	2-[4-(4-fluoro-2-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A37"	2-[4-(2,4-dimethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A38"	2-[4-(2-chloro-4-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A39"	2-[4-(2-chloro-4-fluoro-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A40"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]acetamide
"A41"	2-(3-phenylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A42"	2-[4-(2-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A43"	2-[4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A44"	2-[4-(6-methoxypyridazin-3-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A45"	4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile

"A46"	2-[4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]phenyl]acetonitrile
"A47"	2-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A48"	2-[4-(4-ethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A49"	2-[4-(4-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A50"	2-[4-(4-trifluoromethylphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A51"	2-[4-(6-methoxy-3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A52"	2-[4-(5-methoxy-2-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A53"	2-[4-hydroxy-4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A54"	2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A55"	2-[4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A56"	2-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A57"	2-[4-[2-(1-hydroxy-1-methyl-ethyl)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

3. Compounds according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

4. Compounds according to claim 3 for use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.

5. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

6. Set (kit) consisting of separate packs of

(a) an effective amount of a compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

7. The compound 2-(4-tert-butyl-piperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one ("B1"), and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.